See Important Reminder at the end of this policy for important regulatory and legal information.

Transcription

1 Clinical Policy: (Grastek, Oralair, Ragwitek) Reference Number: CP.CPA.111 Effective Date: Last Review Date: Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The following are allergen-specific immunotherapy agents requiring prior authorization: Short Ragweed Pollen Allergen Extract (Ragwitek ), Timothy Grass Pollen Allergen Extract (Grastek ), and Sweet Vernal/Orchard/Perennial Rye/Timothy/Kentucky Blue Grass Mixed Pollens Allergen Extract (Oralair ). FDA approved indication Ragwitek is indicated for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Grastek is indicated for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens. Oralair is indicated for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in this product. Limitation of use: Ragwitek is approved for use in adults 18 through 65 years of age. Grastek is approved for use in person 5 through 65 years of age. Oralair is approved for use in person 10 through 65 years of age. Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria It is the policy of health plans affiliated with Centene Corporation that Ragwitek, Grastek and Oralair are medically necessary when the following criteria are met: I. Initial Approval Criteria A. Allergic Rhinitis (must meet all): 1. Diagnosis of allergic rhinitis; 2. One of the following (a or b): a. Prescribed by or in consultation with an allergist/immunologist; Page 1 of 6

2 b. Positive skin test or in vitro testing for pollen-specific IgE antibodies for allergens based on the requested drug (Ragwitek: short ragweed pollen, Grastek: Timothy grass or cross reactive species [Sweet vernal, Meadow fescue, Rye, June, Kentucky blue, Orchard, Red top, Velvet, Canary, Cereal grains (e.g., wheat, rye, barley)], Oralair: Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass. 3. Failure of maximally tolerated doses of 2 of the following unless contraindicated or clinically significant adverse effects are experienced: oral antihistamines, leukotriene modifiers or nasal steroids; 4. Dose does not exceed: a. Ragwitek: 12 Amb a 1-U/day; b. Grastek: 2800 BAU/day; c. Oralair: 300 IR/day. Approval duration: Length of Benefit B. Other diagnoses/indications 1. Refer to CP.CPA.09 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). II. Continued Therapy A. Allergic Rhinitis (must meet all): 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; 2. Dose does not exceed: a. Ragwitek: 12 Amb a 1-U/day; b. Grastek: 2800 BAU/day; c. Oralair: 300 IR/day. Approval duration: Length of Benefit B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy. Approval duration: Duration of request or 12 months (whichever is less); or 2. Refer to CP.CPA.09 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized). III. Diagnoses/Indications for which coverage is NOT authorized: A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy CP.CPA.09 or evidence of coverage documents. IV. Appendices/General Information Appendix A: Abbreviation/Acronym Key IgE: Immunoglobulin E Amb a 1-U: arbitrary measurement of major allergen BAU: Bioequivalent Allergy Units Page 2 of 6

3 IR: index of reactivity Appendix B: General Information Patients should have confirmed IgE-mediated allergic reaction. All agents can cause life-threatening allergic reactions such as anaphylaxis and severe layngopharyngeal restriction. No agent should be given to patients with severe, unstable, or uncontrolled asthma. Patients should be observed for at least 30 minutes following the initial dose. Patients should have an auto-injectable epinephrine and be instructed on its appropriate use. Agents may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators such as those taking beta-blockers. All agents are contraindicated in patients with a history of eosinophilic esophagitis. Safety and efficacy of Oralair in the pediatric population >= 5 years of age was demonstrated in a randomized clinical trial. Grastek was studied in patients for 3 years; patients maintained the effect for 1 year after discontinuing the drug, but not for the 2 nd year. Appendix C: Therapeutic Alternatives Drug Dosing Regimen Dose Limit/Maximum Dose Subcutaneous Various Various Immunotherapy (SCIT) OTC loratadine (Claritin ) 2 to 5 years: 5 mg PO QD 6 years: 10 mg/day OTC loratadine-d (Claritin-D 12 and 24 hour) OTC cetirizine (Zyrtec ) OTC fexofenadine (Allegra Allergy ) fluticasone priopionate (Flonase ) 10 mg PO QD 1 tablet PO BID (12 hr) QD (24 hr) 2 to 5 years: mg PO QD 6 years: 10 mg PO QD 6-months to 2 years: 15 mg PO QD 2 to 11 years: 30 mg PO QD 60 mg PO BID or 180 mg PO QD 4 years: 1-2 sprays each nostril QD 1-2 sprays each nostril QD 10 mg/day 10 mg/day 180 mg/day 2 sprays each nostril/day Page 3 of 6

4 Drug Dosing Regimen Dose Limit/Maximum Dose triamcinolone acetonide (Nasacort AQ ) Nasonex (mometasone furoate monohydrate) azelastine (Astelin, Astepro) Montelukast (Singulair) 1 spray each nostril QD 1-2 sprays each nostril QD 1 spray each nostril QD 2 sprays each nostril QD 5-11 years: 1 spray each nostril BID 1-2 sprays each nostril BID or 2 sprays each nostril QD 2 to 5 years: 4mg PO QD 6 to 14 years: 5 mg PO QD 1 spray each nostril/day >12 years: 2 sprays each nostril/day 1 spray each nostril/day >12 years: 2 sprays each nostril/day 4 sprays each nostril/day 10 mg /day > 15 years: 10 mg PO QD Therapeutic alternatives are listed as Brand name (generic) when the drug is available by brand name only and generic (Brand name ) when the drug is available by both brand and generic. V. Dosage and Administration Drug Name Dosing Regimen Maximum Dose Ragwitek 1 tablet SL QD, starting 12 weeks before 12 Amb a 1-U/day and continuing throughout the ragweed pollen season. Grastek Ages 5 years: 1 tablet SL QD, starting BAU/day weeks before and continuing throughout the grass pollen season. Oralair Ages years: 300 IR SL QD 300 IR/day Ages years: Day 1: 100 IR, Day 2: 2x100 IR, Day 3 and continuing: 300 IR SL QD Initiate treatment 4 months prior to and continuing throughout the grass pollen season. VI. Product Availability Drug Ragwitek Grastek Oralair Availability Sublingual tablet 12 Amb a 1-Unit (Amb a 1-U) Sublingual tablet: 2800 BAU Sublingual tablet: 100 IR and 300 IR Page 4 of 6

5 VII. References 1. Ragwitek [Prescribing Information] Whitehouse Station, NJ: Merck & Co., Inc.; September Grastek [Prescribing Information] Whitehouse Station, NJ: Merck & Co., Inc.; September Oralair [Prescribing Information] Antony, France: Stallergenes S.A; October Oralair: FDA Allergenic Products Advisory Committee Briefing Document: November Available at: therbiologics/allergenicproductsadvisorycommittee/ucm htm. Last accessed January 12, Wahn U et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjuncitivitis. J Allergy Clin Immunol 2009;123: e3 6. Didier A, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011; 128: Cox L, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012;130: e.1 8. Micromedex Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed January 12, Clinical Pharmacology Web site. Available at: Accessed January 12, Ragwitek. American Hospital Formulary Service Drug Information. Available at: Accessed January 12, Oralair. American Hospital Formulary Service Drug Information. Available at: Accessed January 12, Grastek. American Hospital Formulary Service Drug Information. Available at: Accessed January 12, Reviews, Revisions, and Approvals Date P&T Approval Date Converted to new template. Minor changes to verbiage and grammar. References updated Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice Page 5 of 6

6 current at the time that this clinical policy was approved. Health Plan means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan s affiliates, as applicable. The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures. This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time. This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan. This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene and Centene Corporation are registered trademarks exclusively owned by Centene Corporation. Page 6 of 6